8-K: Collegium Pharma Reports Q2 Growth, Boosted by AZSTARYS Acquisition

Collegium Pharmaceutical announced strong second-quarter 2026 results, with net revenues up 6% year-over-year, driven by significant growth in its ADHD portfolio, particularly JORNAY PM, and the successful acquisition of AZSTARYS.

Summary

• Collegium Pharmaceutical reported second-quarter 2026 net revenues of $199.9 million, a 6% increase compared to the same period last year.
• JORNAY PM demonstrated strong performance with a 41% year-over-year revenue increase to $46.1 million, and a 13.1% rise in prescriptions.
• The acquisition of AZSTARYS was completed in May 2026, contributing $12.9 million in net revenue for a partial quarter.
• The pain portfolio generated $140.9 million in net revenues, a 9% decrease year-over-year.
• Full-year 2026 financial guidance was updated, with a reaffirmation for JORNAY PM and an increase for AZSTARYS revenue, while overall product revenues and Adjusted EBITDA guidance were lowered due to lower-than-expected revenue from Nucynta franchise authorized generics.
• Adjusted EBITDA for the quarter increased by 8% year-over-year to $113.8 million.
• The company generated $71.3 million in cash from operations and ended the quarter with $129.5 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong growth in the ADHD portfolio and successful integration of a key acquisition, despite some headwinds in the pain segment.

Positives

• Total net revenues increased by 6% year-over-year to $199.9 million.
• JORNAY PM net revenue grew significantly by 41% year-over-year to $46.1 million.
• JORNAY PM prescriptions increased by 13.1% year-over-year.
• Over 30,000 healthcare providers wrote JORNAY PM prescriptions, a 17.6% year-over-year increase.
• The acquisition of AZSTARYS was successfully completed and integrated, contributing $12.9 million in net revenue in its first partial quarter.
• AZSTARYS prescriptions grew 1.9% in the quarter.
• Adjusted EBITDA increased by 8% year-over-year to $113.8 million.
• Generated strong operating cash flow of $71.3 million.

Negatives

• Pain portfolio net revenues decreased by 9% year-over-year to $140.9 million.
• Xtampza ER net revenue decreased by 14% year-over-year to $45.0 million.
• Nucynta Franchise net revenue decreased by 24% year-over-year to $35.2 million, including $5.1 million from authorized generics.
• GAAP net loss for the quarter was $15.1 million, compared to a GAAP net income of $12.0 million in the prior year's quarter.
• Full-year 2026 guidance for total Product Revenues, Net was decreased to $825-$855 million from $865-$895 million.
• Full-year 2026 guidance for Adjusted EBITDA was decreased to $445-$470 million from $475-$500 million.

Risks

• The decreases in Product Revenues, Net and Adjusted EBITDA guidance are largely driven by lower-than-expected revenue from the AG versions of Nucynta and Nucynta ER due to lower net pricing.
• Potential risks associated with the AZSTARYS acquisition include the possibility that expected benefits may not be realized or not within the expected time period, and the risk of unsuccessful integration.
• Future opportunities and plans for products carry uncertainty regarding expected financial performance.
• The company faces risks related to the success of competing products.
• Maintaining regulatory approval and managing any related restrictions, limitations, or warnings on product labels are ongoing risks.
• The company must manage relationships with licensors.
• There is uncertainty regarding the rate and degree of market acceptance of its products.
• The company faces risks related to obtaining and maintaining sufficient intellectual property protection for its products.

Future Outlook

Full-year 2026 guidance has been updated. JORNAY PM revenue guidance remains unchanged, while AZSTARYS revenue guidance has been raised. However, overall Product Revenues, Net and Adjusted EBITDA guidance have been lowered due to lower-than-expected revenue from Nucynta franchise authorized generics.

Management Comments

• "In the second quarter, we saw strong demand across our ADHD portfolio, highlighted by record-high JORNAY PM prescriptions and prescriber adoption, alongside 41% revenue growth. Importantly, we have completed the acquisition of AZSTARYS and our integration is progressing well, with our expanded salesforce fully trained and deployed ahead of the important back-to-school season."
• "Together, our differentiated ADHD portfolio and established pain business provide a strong foundation for growth and long-term value creation."
• "As we move into the second half of the year, we are focused on three key strategic priorities: driving growth in our ADHD business, maximizing the value of our pain portfolio, and strategically deploying capital to create long-term shareholder value."
• "During the quarter, we delivered solid performance across our business, successfully integrated AZSTARYS and generated robust operating cash flows."
• "As we enter the back-to-school season, our organization is well positioned with two differentiated and complementary ADHD medicines and supported by a single commercial platform that enhances our ability to serve healthcare providers and patients, alike."

Industry Context

StockSavvy.ai notes that Collegium's results reflect ongoing trends in the pharmaceutical industry, particularly the focus on specialized treatments for conditions like ADHD and pain management. The successful integration of AZSTARYS highlights the industry's reliance on strategic acquisitions to bolster product portfolios and market position, while the pressure on pain franchise revenues underscores the competitive landscape and pricing dynamics in that segment.

Comparison to Industry Standards

• The 41% year-over-year growth for JORNAY PM is significantly above the typical growth rates seen for established pharmaceutical products in competitive markets.
• The 6% overall revenue growth is moderate but positive, aligning with expectations for companies managing a diversified portfolio with both growth drivers and mature products.
• The decrease in pain portfolio revenue, particularly for Nucynta franchise, reflects broader industry challenges in the opioid pain management space due to regulatory scrutiny and the shift towards non-opioid alternatives.
• The successful integration of AZSTARYS and its contribution to revenue is a key positive, demonstrating effective post-acquisition execution, which is a critical benchmark for M&A success in the biopharma sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The updated guidance, particularly the reduction in Adjusted EBITDA, may be viewed negatively, but the strong performance of the ADHD portfolio and successful acquisition of AZSTARYS provide a positive outlook for long-term value creation.
• Employees: Recognition as a 'Best Place to Work' and 'Top Workplace' indicates positive employee sentiment and a supportive work environment.
• Healthcare Providers: Continued focus on differentiated ADHD medicines like JORNAY PM and AZSTARYS aims to provide effective treatment options, potentially improving patient care.
• Patients: The company's mission is to improve the lives of people with serious conditions, with a focus on providing differentiated treatment options.

Next Steps

• Focus on driving growth in the ADHD business.
• Maximize the value of the pain portfolio.
• Strategically deploy capital for long-term shareholder value.
• Continue integration of AZSTARYS and leverage the expanded salesforce.
• Participate in upcoming investor conferences in Q3 2026.

Key Dates

Recommendation

The company shows strong growth in its key ADHD segment with the successful acquisition of AZSTARYS, which is a significant positive. However, the decline in the pain portfolio and the downward revision of full-year Adjusted EBITDA guidance due to issues with Nucynta authorized generics introduce uncertainty. While the core growth drivers are performing well, the headwinds in the pain segment and the impact on overall profitability warrant a cautious 'hold' stance until the integration of AZSTARYS is fully realized and the impact of pricing pressures on the Nucynta franchise is clearer.

Keywords

ADHD, JORNAY PM, AZSTARYS, Pain Management, Pharmaceutical, Acquisition, Financial Results, Biopharmaceutical